Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of Camlipixant in Healthy Participants
NCT06497517Phase 1Completed
- Sponsor
- GSK
- Start
- Jul 2024
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of camlipixant in chronic cough (2 arms), sponsored by GSK. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity Post-Dose and Maximum Observed Plasma Drug Concentration. Started Jul 2024; status: completed.
02
Drugs
camlipixant
03
Conditions
chronic cough
Beyond the preview
Go deeper on NCT06497517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06497517.